Science

Regen presents a new paradigm in osteoarthritis treatment: a novel formulation that can improve the overall treatment plan. Regen’s outpatient procedures require minimal training and have been shown to provide favorable outcomes to patients.

Publications. The following contains links to websites owned and operated by third parties. If you use these links you leave our website. These links are provided for your information and convenience only and are not an endorsement by Regen or the content of such linked websites. Regen has no control of the content of any linked website and is not responsible for these websites or their content or availability. Regen therefore makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by or the information contained on them.

Intellectual Property. Regen holds three US issued patents and is about to receive approval in Europe as well.

U.S. Patent No. 9,089,580.

  • Bone and cartilage growth
  • Patent protection until 2033
  • Right to exclude others from using Regen formulation to regenerate bone in the jaw and cartilage

U.S. Patent No. 9,433,629.

  • Treatment of tumors and cysts of the jaw and stimulating periodontium growth
  • Patent protection until 2035
  • Right to exclude others from using Regen formulation to treat tumors and cysts of the jaws and  regenerate compromised tissues

U.S. Patent No. 9,669,074.

  • Bone, cartilage, periodontium and hair growth; treatment of tumors and cysts of the jaws
  • Patent protection until 2035
  • Right to exclude others from using Regen formulation to regenerate bone and cartilage in various parts of the body including joints (e.g. knee)